| 货号 | HV974026 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Human |
| 同种型 | IgG1-kappa |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274 |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q9NZQ7 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | MEDI4736, 1428935-60-7 |
| 背景 | Atezolizumab (trade name Tecentriq) is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). In 2015, it was in clinical trials as an immunotherapy for several types of solid tumors. It was under investigation by Genetech/Roche. In April 2016, Roche announced that atezolizumab had been granted fast track status for lung cancer by the FDA. In May 2018, Tecentriq was in combination with Avastin and standard chemotherapy for some patients with lunch cancer was granted priority review. |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Durvalumab.
Detects Human CD274/PD-L1/B7-H1 in indirect ELISAs.
Flow-cytometry using anti-human CD274 antibody. Untransfected cells (blue Histogram) and Transfected cells (Yellow Histogram) were stained with an anti-human CD274 monoclonal antibody (Catalog HV974036) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
SDS-PAGE for Research Grade Durvalumab.
Flow-cytometry using FITC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an FITC anti-human CD274 monoclonal antibody (Catalog: HV974026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Flow-cytometry using APC anti-human CD274 antibody. MDA-MB-231 cells were stained with an irrelevant antibody (Blue Histogram) or an APC anti-human CD274 monoclonal antibody (Catalog: HV974026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.
Western blot analysis was performed using anti-CD5 monoclonal antibody at 1μg/ml on various samples.
Lane 1: recombinant human CD5 (Catalog No: HY046011), 50ng
Lane 2: recombinant human CD5 (Catalog No: HY046011), 30ng
Lane 3: recombinant human CD5 (Catalog No: HY046011), 20ng
Lane 4: recombinant human CD5 (Catalog No: HY046011), 10ng
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
